Lyell Immunopharma Stock Z Score
| LYEL Stock | USD 0.95 0.03 3.26% |
Lyell | Z Score |
Lyell Immunopharma Company Z Score Analysis
Lyell Immunopharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Lyell Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Lyell Immunopharma is extremely important. It helps to project a fair market value of Lyell Stock properly, considering its historical fundamentals such as Z Score. Since Lyell Immunopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lyell Immunopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lyell Immunopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Lyell Immunopharma has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Lyell Immunopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Lyell Immunopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lyell Immunopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lyell Immunopharma's value.| Shares | Sc China Holding Ltd | 2024-09-30 | 3 M | Mic Capital Management Uk Llp | 2024-09-30 | 1.7 M | Opaleye Management Inc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Balyasny Asset Management Llc | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 1 M | Td Asset Management Inc | 2024-09-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 901.5 K | Mwg Management Ltd. | 2024-06-30 | 20.2 M | Orland Properties Ltd | 2024-06-30 | 15.1 M |
Lyell Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (125.21 M) | ||||
| Shares Outstanding | 279.22 M | ||||
| Shares Owned By Insiders | 14.06 % | ||||
| Shares Owned By Institutions | 61.64 % | ||||
| Number Of Shares Shorted | 9.6 M | ||||
| Price To Earning | 3.66 X | ||||
| Price To Book | 0.50 X | ||||
| Price To Sales | 4,189 X | ||||
| Revenue | 130 K | ||||
| Gross Profit | 84.68 M | ||||
| EBITDA | (226.76 M) | ||||
| Net Income | (234.63 M) | ||||
| Cash And Equivalents | 655.56 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 63.17 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.26 X | ||||
| Book Value Per Share | 2.07 X | ||||
| Cash Flow From Operations | (163.69 M) | ||||
| Short Ratio | 5.18 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 224 | ||||
| Beta | -0.48 | ||||
| Market Capitalization | 263.89 M | ||||
| Total Asset | 750.03 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 520.17 M | ||||
| Net Asset | 750.03 M |
About Lyell Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lyell Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyell Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyell Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lyell Immunopharma Piotroski F Score and Lyell Immunopharma Valuation analysis. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.